HRA2pl peptide: a fusion inhibitor for human metapneumovirus produced in tobacco plants by transient transformation

Planta

Volumn 242, Issue 1, 2015, Pages 69-76

  Márquez Escobar, Verónica A ^a   Tirado Mendoza, Rocío ^b   Noyola, Daniel E ^c   Gutiérrez Ortega, Abel ^d   Alpuche Solís, Ángel G ^a  

^a INSTITUTO POTOSINO DE INVESTIGACIÓN CIENTÍFICA Y TECNOLÓGICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^d CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO   (Mexico)

Author keywords

Antiviral peptide; hMPV; HRA domain; Transient transformation

Indexed keywords

HUMAN METAPNEUMOVIRUS; NICOTIANA OBTUSIFOLIA; NICOTIANA TABACUM;

ANTIVIRUS AGENT; HRA2PL PEPTIDE; PEPTIDE;

AMINO ACID SEQUENCE; BIOASSAY; CELL DEATH; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENETIC TRANSFORMATION; GENETICS; HUMAN; METAPNEUMOVIRUS; MOLECULAR GENETICS; PARAMYXOVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; TOBACCO; TRANSGENIC PLANT; TUMOR CELL LINE; VIROLOGY; VIRUS ENTRY;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CELL DEATH; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; METAPNEUMOVIRUS; MOLECULAR SEQUENCE DATA; PARAMYXOVIRIDAE INFECTIONS; PEPTIDES; PLANTS, GENETICALLY MODIFIED; TOBACCO; TRANSFORMATION, GENETIC; VIRUS INTERNALIZATION;

EID: 84938080669     PISSN: 00320935     EISSN: 14322048     Source Type: Journal    
DOI: 10.1007/s00425-015-2277-5     Document Type: Article

References (36)

1. Alvarez ML, Topal E, Martin F, Cardineau GA (2010) Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation. Plant Mol Biol 72:75–89
2. Baker KA, Dutch RE, Lamb RA, Jardetzky TS (1999) Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 3:309–319
3. Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, Peret TC, Erdman DD, Anderson LJ (2002) Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 186:1330–1334
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
5. Daniell H, Singh ND, Mason H, Streatfield SJ (2009) Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 14:669–679. doi:10.1016/j.tplants.2009.09.009
6. Davoodi-Semiromi A, Samson N, Daniell H (2009) The green vaccine: a global strategy to combat infectious and autoimmune diseases. Hum Vaccines 5(7):488–493. doi:10.4161/hv.8247
7. Deffrasnes C, Hamelin ME, Prince GA, Boivin G (2008) Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Ch 52(1):279–287. doi:10.1128/aac.00793-07
8. Eckardt-Michel J, Lorek M, Baxmann D, Grunwald T, Keil GM, Zimmer G (2008) The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis. J Virol 82(7):3236–3249. doi:10.1128/jvi.01887-07
9. Eckert DM, Kim PS (2001a) Design of potent inhibitors of HIV-1 entry from the gp41N-peptide region. Proc Natl Acad Sci USA 98:11187–11192. doi:10.1073/pnas.201392898
10. Eckert DM, Kim PS (2001b) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70:777–810. doi:10.1146/annurev.biochem.70.1.777
11. Gleba Y, Klimyuk V, Marillonnet S (2005) Magnifection—a new platform for expressing recombinant vaccines in plants. Vaccine 23(17–18):2042–2048. doi:10.1016/j.vaccine.2005.01.006
12. Hahn A, Wang W, Jaggi P, Dvorchik I, Ramilo O, Koranyi K, Mejias A (2013) Human metapneumovirus infections are associated with severe morbidity in hospitalized children of all ages. Epidemiol Infect 141(10):2213–2223. doi:10.1017/s0950268812002920
13. Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N (2013) Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides. Antimicrob Agents Chemother 57(5):2076–2086. doi:10.1128/aac.02588-12
14. Herfst S, Fouchier RA (2008) Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J Clin Virol 41(1):49–52. doi:10.1016/j.jcv.2007.10.022
15. Kitanovski L, Kopriva S, Pokorn M, Dolnicar MB, Rajic V, Stefanovic M, Jazbec J (2013) Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol 35:e311–e313
16. Lamb RA, Paterson RG, Jardetzky TS (2006) Paramyxovirus membrane fusion: lesson from the F and HN atomic structures. Virology 344:30–37. doi:10.1016/j.virol.2005.09.007
17. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA 93(5):2186–2191
18. Lawless-Delmedico MK, SistaP Sen R, Moore NC, Antczak JB, White JM, Greene RJ, Leanza KC, Matthews TJ, Lambert DM (2000) Heptad repeat regions of respiratory syncytial virus F1 protein form a sixmembered coiled-coil complex. Biochem US 39:11684–11695
19. Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y (2004) In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci USA 101(18):6852–6857. doi:10.1073/pnas.0400149101
20. Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba Y (2005) Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol 23(6):718–723. doi:10.1038/nbt1094
21. Miller SA, Tollefson S, Crowe JE Jr, Williams JV, Wright DW (2007) Examination of a fusogenic hexameric core from human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptad repeat 1 region. J Virol 81(1):141–149. doi:10.1128/jvi.01243-06
22. Noyola DE, Alpuche-Solis AG, Herrera-Diaz A, Soria-Guerra RE, Sanchez-Alvarado J, Lopez-Revilla R (2005) Human metapneumovirus infections in Mexico: epidemiological and clinical characteristics. J Med Microbiol (Pt 10):969–974. doi:10.1099/jmm.0.46052-0
23. Root MJ, Kim PS, Kay MS (2001) Protein design of an HIV-1 entry inhibitor. Science 291:884–888
24. Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5(4):725–738. doi:10.1038/nprot.2010.5
25. Russell CJ, Jardetzky TS, Lamb RA (2001) Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J 20(15):4024–4034. doi:10.1093/emboj/20.15.4024
26. Schillberg S, Twyman RM, Fischer R (2005) Opportunities for recombinant antigen and antibody expression in transgenic plants—technology assessment. Vaccine 23(15):1764–1769. doi:10.1016/j.vaccine.2004.11.002
27. Streatfield SJ, Howard JA (2003) Plant production systems for vaccines. Expert Rev vaccines 2(6):763–775. doi:10.1586/14760584.2.6.763
28. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD (2001) A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7(6):719–724. doi:10.1038/89098
29. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA (2002) Analysis of the genomic sequence of a human metapneumovirus. Virology 295(1):119–132. doi:10.1006/viro.2001.1355
30. van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo-Neto E, de Swart RL, Osterhaus AD, Fouchier RA (2004) Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 10(4):658–666. doi:10.3201/eid1004.030393
31. Wang XJ, Bai YD, Zhang GZ, Zhao JX, Wang M, Gao GF (2005) Structure and function study of paramyxovirus fusion protein heptad repeat peptides. Arch Biochem Biophys 436:316–322. doi:10.1016/j.abb.2005.02.004
32. WHO (2013) http://www.who.int/vaccine_research/diseases/ari/en/
33. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91:9770–9774
34. Yao Q, Compans RW (1996) Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology 223(1):103–112. doi:10.1006/viro.1996.0459
35. Yusibov V, Mett V, Mett V, Davidson C, Musiychuk K, Gilliam S, Farese A, Macvittie T, Mann D (2005) Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine 23(17–18):2261–2265. doi:10.1016/j.vaccine.2005.01.039
36. Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim do H, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE Jr, Piedra PA, Gilbert BE (2013) Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. mAbs 5(2):263–269. doi:10.4161/mabs.23281